<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="sct312264-tbl-0001" xml:lang="en" orientation="portrait" position="float">
 <label>Table 1</label>
 <caption>
  <p>Inclusion and exclusion criteria</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-bottom:solid 1px #000000border-right:solid 1px #000000" width="80pt" span="1"/>
  <tbody valign="top">
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <bold>Inclusion criteria</bold>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"> a Age range: 18–75 years.
     <break/> b. Sex: male or female.
     <break/> c. Patient must have diagnosis of treatment refractory BO/BOS, must have had either an inadequate or lost response (recurrence or persistence of symptoms) to a drug in each of the following three treatment categories within the past 24 months or documented intolerance to a drug in that category at any time: (a) enhanced steroid therapy; (b) enhanced immunosuppression; (c) trial/failure to other therapies like azithromycin, anti‐reflux therapy, statin agents, and/or use of alternate immunosuppressive agents like Thymoglobulin
     <xref ref-type="fn" rid="sct312264-note-0001">a</xref>, methotrexate, or Rapamune
     <xref ref-type="fn" rid="sct312264-note-0002">b</xref>.
     <break/> d. Patient must have adequate renal function; calculated creatinine clearance &gt;30 ml/min.
     <break/> e. Patient must be available for all specified assessments at the study site through the completion of the study.
     <break/> f. Patient must provide written informed consent.
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <bold>Exclusion criteria</bold>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1"> a. Patients with clinically significant illness with manifestations of significant organ dysfunction, which in the judgment of the principal or coinvestigator would render the patient unlikely to tolerate the MSC infusion or complete the study.
     <break/> b. Evidence or history of malignancy.
     <break/> c. Evidence or history of autoimmune disorders independent of BO/BOS.
     <break/> d. Pregnant or breast‐feeding.
     <break/> e. Positive screening for HIV, hepatitis B, and hepatitis C.
     <break/> f. Evidence of liver dysfunction; total bilirubin &gt;1.65 mg/dL, ALT &gt;275 units per L, and AST &gt;240 units per L.
     <break/> g. Evidence of significant cardiac dysfunction.
     <break/> h. Septicemia with high fever and hemodynamic instability.
     <break/> i. History of CMV pneumonitis.
     <break/> j. Patients who received any experimental therapy (drug or biologic) for any indication within 3 months of the study enrollment.
     <break/> k. Patient qualifies for retransplantation.
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="sct312264-note-0001">
   <label>a</label>
   <p>Anti‐thymocyte globulin [rabbit]; Sanofi, Paris, France, 
    <ext-link ext-link-type="uri" xlink:href="http://www.sanofi.us/l/us/en/index.jsp" xmlns:xlink="http://www.w3.org/1999/xlink">http://www.sanofi.us/l/us/en/index.jsp</ext-link>.
   </p>
  </fn>
  <fn id="sct312264-note-0002">
   <label>b</label>
   <p>Sirolimus; Pfizer, New York, NY, 
    <ext-link ext-link-type="uri" xlink:href="https://www.pfizer.com" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.pfizer.com</ext-link>.
   </p>
  </fn>
  <fn id="sct312264-note-0003">
   <p>Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; BO/BOS, bronchiolitis obliterans/bronchiolitis obliterans syndrome; CMV, cytomegalovirus; MSC, mesenchymal stem cell.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
